IDEAYA Biosciences (IDYA) R&D Day 2025 summary

Pipeline overview and program updates

• Advanced seven clinical to IND-stage programs in precision oncology, with two more INDs expected by year-end.

• Pipeline targets high unmet needs in cancers such as uveal melanoma, lung, colorectal, and gynecological cancers.

• Darovasertib positioned as a potential standard of care in uveal melanoma across neoadjuvant, adjuvant, and metastatic settings.

• IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) highlighted as next clinical growth drivers.

• Broadest MTAP-deletion pipeline in the industry, including IDE397 (MAT2A inhibitor) and IDE892 (PRMT5 inhibitor).

Clinical trial data and development milestones

• OPTIMUM-09 trial: Darovasertib showed a 76% overall response rate in neoadjuvant uveal melanoma, with significant tumor shrinkage and vision preservation.

• Registration trial OptimUM-10 initiated for darovasertib, focusing on vision and eye preservation endpoints.

• IDE849 first-in-human trial in small cell lung cancer showed a 70% confirmed response rate at 2.4 mg/kg, with a disease control rate over 90%.

• Trodelvy plus IDE397 combination in MTAP-deleted urothelial cancer showed a 57% partial response rate at optimal dose, with favorable safety.

• IDE892 (PRMT5 inhibitor) IND filed, with strong preclinical and combination activity in MTAP-null models.

R&D strategy and innovation priorities

• Focus on first-in-class targets, biomarker-driven patient selection, and rational drug combinations.

• Emphasis on early-stage disease intervention and integration of AI/ML for accelerated drug discovery.

• Structure-based drug design and in-house AI/ML capabilities drive productivity and innovation.